Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DII235 in Adults With Elevated Lipoprotein(a)
NCT07235046Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Biologic
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of BW-20829 in lipoprotein disorder (5 arms), sponsored by Novartis. Primary endpoints: Time averaged percentage change from baseline in Lp(a) between Day 60 and Day 180, Difference between DII235 dose 2 and placebo in time-averaged percent change from baseline in Lp(a) measured between Day 60 and Day 360 and 1 more. Started Dec 2025; status: active, not recruiting.
02
Drugs
BW-20829
03
Conditions
lipoprotein disorder
Beyond the preview
Go deeper on NCT07235046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235046.